This application is a competing renewal application of GM62437 that concerns chemical approaches to sorting out the mechanisms, regulation, and functions of acetyltransferase and demethylase enzymes that modify histones and other proteins. p300/CBP histone acetyltransferase (HAT) and LSD1 histone demethylase are key enzymes that regulate gene expression and are potential therapeutic targets in a range of diseases. p300/CBP is a broadly acting HAT that has been implicated in modulating cancer pathways, endocrine disorders, immune signaling, and learning and memory. LSD1 is a transcriptional repressor that removes methyl groups from Lys4 of histone H3. In this application, we plan to build on our recent progress regarding structural analysis of the p300/CBP HAT domain and the LSD1 catalytic domain in complex with our synthetic inhibitors. There are four specific aims: 1) Determine the scope and mechanisms of p300/CBP HAT catalysis and regulation based on the p300 HAT X-ray structure. In this regard, we will investigate the role of the p300/CBP L1 loop and the autoregulatory loop using mutagensis and by employing expressed protein ligation. 2) Develop a new generation of selective small molecule HAT inhibitors and apply these to gene regulation and disease model studies. Virtual ligand screening will be employed based on the crystal structures of p300/CBP HAT and PCAF/GCN5 HAT in complex with bisubstrate analogs. 3) Determine the basis for LSD1 histone demethylase substrate recognition. Chemical and biochemical strategies will be used to discern the potential role of a substrate gamma turn. 4) Develop synthetic inhibitors for the modulation of LSD1 activity in cells and for use in proteomics analysis. Leads will be developed from propargylamine and hydrazine scaffolds. Taken together, these studies have the potential to uncover important insights into the basis of chromatin remodeling and define new directions for pharmacologic intervention.
There is increasing interest in the biology and pharmacology of epigenetics. This application addresses two key enzymes involved in the regulation of epigenetic chromatin remodeling. Insights obtained from this research plan could lead to new therapeutic strategies for cancer, diabetes, immune disorders, and neuropsychiatric conditions.
|Maksimoska, Jasna; Segura-Peña, Dario; Cole, Philip A et al. (2014) Structure of the p300 histone acetyltransferase bound to acetyl-coenzyme A and its analogues. Biochemistry 53:3415-22|
|Yan, Gai; Eller, Mark S; Elm, Courtney et al. (2013) Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells. J Invest Dermatol 133:2444-52|
|Taylor, Martin S; Ruch, Travis R; Hsiao, Po-Yuan et al. (2013) Architectural organization of the metabolic regulatory enzyme ghrelin O-acyltransferase. J Biol Chem 288:32211-28|
|Schröder, Sebastian; Herker, Eva; Itzen, Friederike et al. (2013) Acetylation of RNA polymerase II regulates growth-factor-induced gene transcription in mammalian cells. Mol Cell 52:314-24|
|Tarrant, Mary Katherine; Rho, Hee-Sool; Xie, Zhi et al. (2012) Regulation of CK2 by phosphorylation and O-GlcNAcylation revealed by semisynthesis. Nat Chem Biol 8:262-9|
|Xu, Cheng-Ran; Cole, Philip A; Meyers, David J et al. (2011) Chromatin "prepattern" and histone modifiers in a fate choice for liver and pancreas. Science 332:963-6|
|Wang, Lan; Gural, Alexander; Sun, Xiao-Jian et al. (2011) The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 333:765-9|
|Santer, Frédéric R; Höschele, Philipp P S; Oh, Su Jung et al. (2011) Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther 10:1644-55|
|Karukurichi, Kannan R; Cole, Philip A (2011) Probing the reaction coordinate of the p300/CBP histone acetyltransferase with bisubstrate analogs. Bioorg Chem 39:42-7|
|Tang, Yong; Holbert, Marc A; Delgoshaie, Neda et al. (2011) Structure of the Rtt109-AcCoA/Vps75 complex and implications for chaperone-mediated histone acetylation. Structure 19:221-31|
Showing the most recent 10 out of 35 publications